Roy S. Herbst, MD, PhD, Yale Cancer Center, discusses the use of combination immunotherapy for the treatment of lung cancer.

Herbst says combination immunotherapy makes a lot of sense as we do see some activity with PD-1/PD-L1 agents. However, only about 10% to 20% of patients do benefit from immunotherapy. This leaves 80% of patients in need of more therapy.

Because of this, Herbst believes combination immunotherapies will be critical in the treatment landscape. Moving forward, there must be more evidence on why particular patients respond and don’t respond to these therapies.

Overall, Herbst says that personalizing treatment will help. There needs to be more clinical trials, specifically with biomarkers, so that the right patients can be identified for every treatment.

For more resources and information regarding anticancer targeted therapies in lung cancer: http://targetedonc.com/resource-center/lung